Novo Nordisk’s Ozempic & Wegovy in 2027 Medicare price talks
Novo Nordisk’s (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief. The last round of the Inflation Reduction Act (IRA) negotiations gave Medicare an average 22% […]